Palmitoyl Tetrapeptide-7 vs Palmitoyl Tripeptide-1
A side-by-side research comparison of Palmitoyl Tetrapeptide-7 and Palmitoyl Tripeptide-1 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Palmitoyl Tetrapeptide-7 | Palmitoyl Tripeptide-1 |
|---|---|---|
| Full name | Palmitoyl Tetrapeptide-7 (Pal-GQPR) | Palmitoyl Tripeptide-1 (Pal-GHK) |
| Category | Skin & Anti-Aging | Skin & Anti-Aging |
| Status | Research compound | Research compound |
| Mechanism | Inhibits IL-6 release from keratinocytes and reduces inflammation-mediated MMP activation, preserving existing collagen while complementing Pal-GHK collagen building. | Functions as matrikine signal, mimicking collagen fragments that trigger fibroblasts to produce new collagen. Palmitoyl enables deeper skin penetration. |
| Molecular weight | 693 Da | 578.8 Da |
| Half-life | 8-12 hours (topical) | 8-12 hours (topical) |
| Bioavailability | Good (topical) | Good (topical with lipid modification) |
| Typical dose | 2-4% in formulation | 2-5% in formulation |
| Frequency | 1-2x daily | 1-2x daily |
| Route | Topical | Topical |
Palmitoyl Tetrapeptide-7 reported benefits
- Anti-inflammatory (skin)
- Reduces IL-6
- Prevents collagen degradation
- Combats inflammaging
Palmitoyl Tripeptide-1 reported benefits
- Collagen synthesis stimulation
- Matrix remodeling
- Wrinkle reduction
- Skin thickness increase
Related comparisons
Research and educational reference only. Not medical advice.